Healthcare · NSE: INDGN
Indegene
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 30 Oct 2026 · Read the filing on NSEFiling
- M.Cap
- ₹15,962Cr
- P/E
- 38.8×
- 1Y return
- +29.92%
- From 52W high
- −2.2%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 1,122 | 804 | +39.6% | 1,063 | +5.6% |
| EBITDA | 186 | 141 | +32.1% | 174 | +6.6% |
| EBITDA margin | 16.6% | 17.5% | -93 bps | 16.4% | +16 bps |
| PBTProfit before tax | 147 | 133 | +10.7% | 153 | -3.5% |
| Net profit | 112 | 102 | +10.0% | 116 | -3.4% |
| EPS (₹) | 4.64 | 4.23 | +9.7% | 4.81 | -3.5% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q2 FY26 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.
Guidance
Goal restated: organic growth rate better than FY26; no formal guidance
Manish Gupta · Chairman and Chief Executive Officer · p. 9
Goal restated: organic growth rate better than FY26; no formal guidance
“While we do not provide formal guidance, I want to restate 2 goals we had set for ourselves and discussed with you all. First, organic growth rate better than FY26 with our biggest relationships and our newer ones moving forward together as we did this quarter.”
This year expected organically stronger than last year; H2 stronger than H1
Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 15
This year expected organically stronger than last year; H2 stronger than H1
“We believe this year should be organically a stronger year than last year, and H2 would be stronger than H1.”
Quarterly EBITDA margins expected back in historical range by Q4
Manish Gupta · Chairman and Chief Executive Officer · p. 9
Quarterly EBITDA margins expected back in historical range by Q4
“The second one was our quarterly EBITDA margins back in our historical range by Q4, as Suhas mentioned, as our go-to-market investments and successes in deal wins get into full-scale execution reflecting in the revenue through this period.”
More figures from the call
“At the same time, more than $400 billion worth of revenue faces patent expiry over the next decade. For us, that translates into demand.”
In short
- 01Management kept its path to quarterly EBITDA margins of 19% plus by Q4 FY27.
- 02Q2 revenue was INR11,223 million, up 39.5% year-on-year; EBITDA margin was 16.7%.
- 03Management restated the goal of organic growth better than FY26, and said H2 should be stronger than H1.
- 04The wage hike cut margins by about 150 bps; lower treasury yields hit PBT by about 90 bps.
- 05PBT is expected to gain up to 90 to 95 bps from lower amortisation and higher yields.
- 069 deal wins above about $1 million in annual value, including one above $5 million and two of $3-5 million.
- 07Revenue from the $10 million outcome-based contract is expected to peak in Q4.
- 08BioPharm earn-out expected close to maximum; the amount is already provided for.
Order book
9 deal wins of about $1 million ACV, incl. one $5 million-plus and two $3-5 million
Manish Gupta · Chairman and Chief Executive Officer · p. 5
9 deal wins of about $1 million ACV, incl. one $5 million-plus and two $3-5 million
“9 deal wins with annual contract values about $1 million, including 3 large deals, one in the $5 million-plus range and 2 in the $3 million to $5 million range.”
Enterprise Commercial: Largest win: top 5 customer mandate to migrate content platform outside the U.S.
Manish Gupta · Chairman and Chief Executive Officer · p. 5
Enterprise Commercial: Largest win: top 5 customer mandate to migrate content platform outside the U.S.
“In the largest new deal win of this quarter, we won a mandate from our existing top 5 customer to migrate the content platform in new geographies outside the U.S.”
Enterprise Commercial: Largest deal work started in Q3; ramp-up likely to impact Q4 and beyond
Manish Gupta · Chairman and Chief Executive Officer · p. 5
Enterprise Commercial: Largest deal work started in Q3; ramp-up likely to impact Q4 and beyond
“While the work commenced in Q3, the ramp-up will likely impact Q4 and beyond.”
Enterprise Commercial: Top 20 pharma consulting work became a global content factory mandate
Manish Gupta · Chairman and Chief Executive Officer · p. 5
Enterprise Commercial: Top 20 pharma consulting work became a global content factory mandate
“A top 20 pharma company had bought us in for a change management consulting engagement. Last quarter, we described it then as a sub-million start with a real room to grow. One quarter later, it has become a mandate to set up a global content factory across Commercial and Medical content for the company's international business.”
Enterprise Commercial: Top 30 pharma deal to manage global digital content, replacing a large incumbent
Manish Gupta · Chairman and Chief Executive Officer · p. 5
Enterprise Commercial: Top 30 pharma deal to manage global digital content, replacing a large incumbent
“Finally, the last large deal win is from a top 30 global pharma company to manage their global digital content where we are replacing a large incumbent.”
Segments
Enterprise Commercial: Revenue mix: Enterprise Commercial about 71%, Enterprise Medical 25%, Others 4%
Suhas Prabhu · Chief Financial Officer · p. 8
Enterprise Commercial: Revenue mix: Enterprise Commercial about 71%, Enterprise Medical 25%, Others 4%
“The business mix was steady with Enterprise Commercial contributing about 71% of our revenue and Enterprise Medical 25%, followed by Others at 4%.”
North America: Geography mix: North America 74%, Europe 23%, rest of world 3%
Suhas Prabhu · Chief Financial Officer · p. 8
North America: Geography mix: North America 74%, Europe 23%, rest of world 3%
“By geography, North America continued to be the highest contributor, accounting for 74%, followed by Europe at 23% and the rest of the world, 3%.”
Tectonic: Tectonic run rate $1.7 million a quarter; contracts above $2 million a quarter
Suhas Prabhu · Chief Financial Officer · Q&A · p. 10
Tectonic: Tectonic run rate $1.7 million a quarter; contracts above $2 million a quarter
“Tectonic has grown from a run rate of about $1 million a quarter to $1.7 million this quarter. And the contracts, as we mentioned, have actually crossed a level of more than $2 million a quarter as we look ahead.”
Enterprise Commercial: Commercial may grow faster than Medical for the next few quarters
Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 14
Enterprise Commercial: Commercial may grow faster than Medical for the next few quarters
“But for the next few quarters, we might see higher growth rates in Commercial.”
Enterprise Medical: Good number of Medical deals in the pipeline
Suhas Prabhu · Chief Financial Officer · Q&A · p. 14
Enterprise Medical: Good number of Medical deals in the pipeline
“But we continue to see a good number of deals in the pipeline in Medical as well.”
Demand
Revenue from largest customer expected to return to an upward path
Suhas Prabhu · Chief Financial Officer · p. 8
Revenue from largest customer expected to return to an upward path
“And as execution catches up, we expect revenue from this client to return to an upward path.”
Top 5 accounts grew 9.2% and top 20 about 6.7% sequentially in INR
Manish Gupta · Chairman and Chief Executive Officer · p. 4
Top 5 accounts grew 9.2% and top 20 about 6.7% sequentially in INR
“Our top 5 accounts grew 9.2% sequentially in INR terms, and our top 20 accounts grew about 6.7%.”
107 active clients, 31 more than a year ago; $1 million-plus clients rose to 59
Manish Gupta · Chairman and Chief Executive Officer · p. 5
107 active clients, 31 more than a year ago; $1 million-plus clients rose to 59
“We now serve 107 active clients, 31 more than a year ago. Clients contributing over $1 million a year rose to 59, up from 54 last quarter.”
Clients above $10 million now number 13, one more than last quarter
Manish Gupta · Chairman and Chief Executive Officer · p. 5
Clients above $10 million now number 13, one more than last quarter
“Clients above $10 million, now numbers 13, one more than last quarter.”
All but one Q2 win was output or outcome-based; share expected to keep rising
Suhas Prabhu · Chief Financial Officer · Q&A · p. 13
All but one Q2 win was output or outcome-based; share expected to keep rising
“most of our wins in the current quarter, Prolin, have been output or outcome-based rather than FTE-based contracts but for one. And that gives us confidence that this number would keep trending upwards.”
Margins and costs
Margin growth in H2 likely to outpace revenue growth by exit of Q4
Suhas Prabhu · Chief Financial Officer · p. 9
Margin growth in H2 likely to outpace revenue growth by exit of Q4
“And as all of this play out, margin growth in H2 is likely to outpace the revenue growth as we exit quarter 4.”
PAT margin expected to expand faster than EBITDA margin in coming quarters
Suhas Prabhu · Chief Financial Officer · p. 8
PAT margin expected to expand faster than EBITDA margin in coming quarters
“This would help our PAT margin expand faster than our EBITDA margin in the coming quarters.”
Amortisation charge to reduce from Q3
Suhas Prabhu · Chief Financial Officer · p. 8
Amortisation charge to reduce from Q3
“Amortization charge will reduce in quarter 3 and beyond.”
Wage hike cut margins by about 150 bps, largely offset by productivity and forex
Suhas Prabhu · Chief Financial Officer · p. 7
Wage hike cut margins by about 150 bps, largely offset by productivity and forex
“And this year, the wage hike impacted margins by about 150 basis points. Improved productivity and favorable exchange rates have largely offset this impact.”
Interest income down 44% sequentially from INR237 million to INR134 million
Suhas Prabhu · Chief Financial Officer · p. 7
Interest income down 44% sequentially from INR237 million to INR134 million
“However, interest income was down 44% sequentially from INR237 million to INR134 million.”
Debt and working capital
Treasury yields expected to rise; portfolio shifting to held-to-maturity instruments
Suhas Prabhu · Chief Financial Officer · p. 8
Treasury yields expected to rise; portfolio shifting to held-to-maturity instruments
“We anticipate yields to increase with the higher interest rates prevailing combined with a conscious shift in the investment portfolio towards a higher allocation to held-to-maturity instruments, which reduce volatility.”
Net DSO up 2 days to 69 days; cash and investments INR13,896 million
Suhas Prabhu · Chief Financial Officer · p. 8
Net DSO up 2 days to 69 days; cash and investments INR13,896 million
“The DSO net of unearned and unbilled revenue was slightly higher at 69 days, up 2 days. And cash and investments stood strong at INR13,896 million.”
Receivables and unbilled expected to return to normal in Q3 and Q4
Suhas Prabhu · Chief Financial Officer · Q&A · p. 10
Receivables and unbilled expected to return to normal in Q3 and Q4
“But we believe going into quarter 3 and quarter 4, we would see the AR and the unbilled more importantly, coming back to what we see normally.”
Acquisitions and new business
BioPharm back-office transition finished by end of February, ahead of March plan
Manish Gupta · Chairman and Chief Executive Officer · p. 6
BioPharm back-office transition finished by end of February, ahead of March plan
“We had planned to transition finance, HR, IT and legal, and close out the seller’s transition services by the end of March. We finished that by the end of February with no disruption to client engagements and strong retention.”
BioPharm cost synergies about $1.5 million a year, reinvested in sales team
Manish Gupta · Chairman and Chief Executive Officer · p. 6
BioPharm cost synergies about $1.5 million a year, reinvested in sales team
“On cost synergies, we have realized around $1.5 million in annual savings, and we reinvested these savings in growth, most visibly by expanding BioPharm's go-to-market team from 3 to 9 people.”
Full BioPharm earn-out amount already provided for in balance sheet
Manish Gupta · Chairman and Chief Executive Officer · p. 7
Full BioPharm earn-out amount already provided for in balance sheet
“Just a caveat, we have already provided for this entire amount in our balance sheet.”
BioPharm data and targeting used in some of the largest pursuits in pipeline
Manish Gupta · Chairman and Chief Executive Officer · p. 7
BioPharm data and targeting used in some of the largest pursuits in pipeline
“We are including BioPharm capabilities in existing and new enterprise omnichannel engagements. Its data and targeting capabilities are now giving us an edge in some of our largest pursuits, which sit in our pipeline right now.”
One-offs
Mutual fund NAV markdown cut yields; hit PBT by about 90 bps and PAT by about 70 bps
Suhas Prabhu · Chief Financial Officer · p. 7
Mutual fund NAV markdown cut yields; hit PBT by about 90 bps and PAT by about 70 bps
“While the invested funds largely remained constant quarter-on-quarter, the markdown in our mutual fund portfolio NAVs due to the increase in interest rates towards the end of the quarter compressed the near-term yields. The quarter-on-quarter impact of lower yields impacted PBT by about 90 basis points and PAT by about 70 basis points.”
Risks
Largest customer revenue eased as Tectonic engagements ramp up more gradually
Suhas Prabhu · Chief Financial Officer · p. 8
Largest customer revenue eased as Tectonic engagements ramp up more gradually
“Revenue from our largest customer slightly eased this quarter as the Tectonic engagements that we signed with them are ramping up more gradually, though the scope we contracted keeps expanding.”
Tectonic ramp-up with largest customer remains slow
Manish Gupta · Chairman and Chief Executive Officer · p. 5
Tectonic ramp-up with largest customer remains slow
“While Tectonic wins continue to accumulate with the largest customer, the ramp-up in this case remains slow.”
Frontier AI labs not seen as a threat; partnership team set up in U.S. and India
Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 10
Frontier AI labs not seen as a threat; partnership team set up in U.S. and India
“We don't see that as a threat to our model of working. We have put a dedicated partnership team in place in the U.S. and India and are partnering with multiple players in the broader tech ecosystem.”
IT companies rarely seen as competitors; main rivals are agencies and CROs
Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 13
IT companies rarely seen as competitors; main rivals are agencies and CROs
“In all transparency, we don't see IT too much, at least in the kind of deals we compete on.”
Largest client's slow ramp put down to central vs local brand team change management
Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 11
Largest client's slow ramp put down to central vs local brand team change management
“Getting those organizational dynamics right in these very, very large companies takes time, given it is a new area.”
Other
Q2 revenue INR11,223 million, up 39.5% year-on-year and 5.6% sequentially
Manish Gupta · Chairman and Chief Executive Officer · p. 4
Q2 revenue INR11,223 million, up 39.5% year-on-year and 5.6% sequentially
“Revenues came in at INR11,223 million, up 39.5% year-on-year and 5.6% sequentially.”
Q2 revenue US$117.5 million, up 27.5% year-on-year and 4.4% sequentially in dollars
Suhas Prabhu · Chief Financial Officer · p. 7
Q2 revenue US$117.5 million, up 27.5% year-on-year and 4.4% sequentially in dollars
“Revenue for the second quarter was INR11,223 million or US$117.5 million. In dollar terms, that is a strong growth of 27.5% year-on-year and 4.4% sequentially.”
Q2 EBITDA INR1,873 million, up 32% year-on-year, margin 16.7%
Suhas Prabhu · Chief Financial Officer · p. 7
Q2 EBITDA INR1,873 million, up 32% year-on-year, margin 16.7%
“EBITDA came in at INR1,873 million, up 32% year-on-year at a margin of 16.7%.”
PBT INR1,474 million; PAT up 10% to INR1,123 million; tax rate 23.8%
Suhas Prabhu · Chief Financial Officer · p. 8
PBT INR1,474 million; PAT up 10% to INR1,123 million; tax rate 23.8%
“Profit before tax was INR1,474 million, with the effective tax rate steady at 23.8%. Profit after tax was up 10% from a year ago at INR1,123 million or 10% of revenue.”
Largest customer 7.8% of revenue; top 10 make up 49%
Suhas Prabhu · Chief Financial Officer · p. 8
Largest customer 7.8% of revenue; top 10 make up 49%
“Our largest customer today represents 7.8% of revenue and our top 10 together make up 49%.”
Sources
- Earnings call transcript, Q2 FY27 Filed 3 Nov 2026 · 16 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

